Page last updated: 2024-12-08
valiolamine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
valiolamine: isolated from Streptomyces hygroscopicus; RN from CA Index; RN not in Chemline 2/85 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 174312 |
| CHEMBL ID | 222396 |
| CHEMBL ID | 9216 |
| MeSH ID | M0127419 |
Synonyms (30)
| Synonym |
|---|
| 83465-22-9 |
| AC-1555 |
| valiolamine hydrate |
| d-epi-inositol, 4-amino-3,4-dideoxy-2-c-(hydroxymethyl)-, hydrate |
| 4-amino-3,4-dideoxy-2-c-(hydroxymethyl)-d-epi-inositol hydrate |
| valiolamine |
| CHEMBL222396 , |
| bdbm50241137 |
| chembl9216 |
| valinolamine |
| 5-amino-1-hydroxymethyl-cyclohexane-1,2,3,4-tetraol |
| bdbm50024129 |
| A840578 |
| (1s,2s,3r,4s,5s)-5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol;valiolamine |
| (1s,2s,3r,4s,5s)-5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol |
| AKOS006287538 |
| (1s,2s,3r,4s,5s)-5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol |
| 4-amino-3,4-dideoxy-2-c-(hydroxymethyl)-d-epi-inositol |
| VDLOJRUTNRJDJO-ZYNSJIGGSA-N |
| mfcd07773061 |
| AS-14081 |
| C76668 |
| 5-amino-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol |
| DTXSID601003447 |
| 4-amino-3.4-dideoxy-2-c-(hydroxymethyl)-d-epi-inositol |
| w9s , |
| QHW83U8Q5B |
| eb-0155 |
| d-epi-inositol, 4-amino-3,4-dideoxy-2-c-(hydroxymethyl)- |
| eb0155 |
Research Excerpts
Overview
Valiolamine is a particularly effective inhibitor of oligosaccharide glucosidases I and II and of lysosomal alpha-glucosidase.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Valiolamine is a particularly effective inhibitor of oligosaccharide glucosidases I and II and of lysosomal alpha-glucosidase." | ( Inhibitory effect of pseudo-aminosugars on oligosaccharide glucosidases I and II and on lysosomal alpha-glucosidase from rat liver. Kamata, K; Kameda, Y; Matsui, K; Takeuchi, M; Yoshida, M, 1990) | 1 |
Effects
Valiolamine has more potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase than valienamine, validamine and hydroxyvalidamine which were reported as building blocks of validamycins.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Valiolamine has more potent alpha-glucosidase inhibitory activity against porcine intestinal sucrase, maltase and isomaltase than valienamine, validamine and hydroxyvalidamine which were reported as building blocks of validamycins and microbial oligosaccharide alpha-glucosidase inhibitors." | ( Valiolamine, a new alpha-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus. Asano, N; Fukase, H; Horii, S; Kameda, Y; Matsui, K; Takeuchi, M; Yamaguchi, T; Yoshikawa, M, 1984) | 2.43 |
| "Valiolamine has more potent carbohydrase inhibitory activity than validamine or valienamine, and the apparent Ki values of valiolamine for sucrase, maltase, glucoamylase, isomaltase and trehalase activities were 3.2 x 10(-7), 2.9 x 10(-6), 1.2 x 10(-6), 9.1 x 10(-7) and 4.9 x 10(-5) M, respectively, which are 10(-5) to 10(-3) times smaller than the apparent Km values." | ( Inhibitory effect of validamine, valienamine and valiolamine on activities of carbohydrases in rat small intestinal brush border membranes. Asano, N; Kameda, Y; Matsui, K; Takai, N; Takeuchi, M, 1990) | 1.25 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (6)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Maltase-glucoamylase, intestinal | Homo sapiens (human) | IC50 (µMol) | 2.2000 | 0.0400 | 3.4652 | 9.0000 | AID104666 |
| Lysosomal alpha-glucosidase | Homo sapiens (human) | IC50 (µMol) | 57.0000 | 0.0600 | 2.2889 | 7.8000 | AID342799 |
| Sucrase-isomaltase, intestinal | Homo sapiens (human) | IC50 (µMol) | 0.0490 | 0.0490 | 2.7294 | 7.8000 | AID208984 |
| Sucrase-isomaltase, intestinal | Rattus norvegicus (Norway rat) | IC50 (µMol) | 1.3950 | 0.0400 | 1.8483 | 10.0000 | AID342795; AID342797 |
| Glycogen debranching enzyme | Oryctolagus cuniculus (rabbit) | IC50 (µMol) | 31.0000 | 0.1100 | 0.6975 | 2.1000 | AID342805 |
| Lysosomal alpha-glucosidase | Rattus norvegicus (Norway rat) | IC50 (µMol) | 18.0000 | 0.0800 | 2.5061 | 9.8500 | AID342793 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (22)
Molecular Functions (10)
Ceullar Components (14)
Bioassays (16)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID208984 | Alpha-D-glucosidase inhibitory activity and enzyme inhibition in vitro against porcine sucrase | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6 | Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. |
| AID104666 | Inhibitory activity against porcine maltase | 1986 | Journal of medicinal chemistry, Jun, Volume: 29, Issue:6 | Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents. |
| AID342793 | Inhibition of rat intestinal brush border membrane maltase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID1895992 | Inhibition of full length human recombinant Endoplasmic reticulum alpha-glucosidase 1 expressed in Escherichia coli using trisaccharide as substrate incubated for 60 mins | 2021 | Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24 | N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. |
| AID342795 | Inhibition of rat intestinal brush border membrane isomaltase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID342804 | Inhibition of rabbit glycogen phosphorylase B at 400 uM | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID1895996 | Antiviral activity against SARS-CoV-2 England/2/2022 assessed as reduction in viral infection | 2021 | Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24 | N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. |
| AID342805 | Inhibition of rabbit muscle amylo-1,6-glucosidase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID342797 | Inhibition of rat intestinal brush border membrane sucrase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID342802 | Inhibition of human lysosomal beta-glucosidase at 1000 uM | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID1895994 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 3 to 5 days by Cell titer-glo luminescent assay | 2021 | Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24 | N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. |
| AID342809 | Inhibition of pig intestinal maltase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID342810 | Inhibition of pig intestinal sucrase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID342799 | Inhibition of human lysosomal alpha-glucosidase | 2008 | Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15 | In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures. |
| AID1895993 | Inhibition of full length N-terminal his6-tagged mouse recombinant Endoplasmic reticulum alpha-glucosidase 2 expressed in DH10 Escherichia coli using Fluorogenic 1,4-methyl-lumbelliferon as substrate preincubated for 60 mins followed by substrate addition | 2021 | Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24 | N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. |
| AID1895995 | Antiviral activity against DENV New Guinea C strain infected in African green monkey Vero cells assessed as reduction in viral infection measured after 5 days by plaque assay | 2021 | Journal of medicinal chemistry, 12-23, Volume: 64, Issue:24 | N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (15)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 21.35
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.35) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 3 (18.75%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (81.25%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||